Lexicon Pharma (LXRX): Price to Sales

Corporate company logo of Lexicon Pharma (LXRX)

The price-to-sales ratio reflects a rapid launch of sales for current heart failure treatments. Lexicon Pharmaceuticals (LXRX) revenues are based on the sale of patented sotagliflozin for diabetes. However, cash flows remain volatile due to the initial stage of the drugs' market rollout. The value of 21.10 shows the current market valuation of the business relative to its annual turnover.

Lexicon Pharmaceuticals, Inc. - LXRX P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Lexicon Pharma (LXRX)

- current price and projected stock value:
Price Chart lexpharma.com|LXRX - Price Target Chart
- stock exchange capitalization data:
Market Value Lexicon Pharma|LXRX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Lexicon Pharmaceuticals|LXRX - Book Capitalization|Market Capitalization to Book Value lexpharma.com|LXRX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Lexicon Pharmaceuticals|LXRX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Lexicon Corp|LXRX - Company Debts|Debt to Book Capitalization Ratio Lexicon Pharma|LXRX - Company Long-Term Debts|Short-Term Debt Lexicon Pharmaceuticals|Immediate Liquidity Ratio lexpharma.com
- financial results and valuation multiples details:
LXRX - Net Profit|Company Profit Forecast Lexicon Pharmaceuticals|LXRX - P/E Multiple|Projected Price to Earnings Lexicon Pharmaceuticals Inc|LXRX - Price/Earnings to Growth Ratio|Company Value to EBITDA Lexicon Pharma|LXRX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Lexicon Pharmaceuticals|LXRX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months lexpharma.com|LXRX - Earnings per share growth in current year|Net earnings per share change forecast for next year Lexicon Pharmaceuticals
- issuer revenue and sales details:
LXRX - Revenue and Sales Volume|Company Future Revenue lexpharma.com|LXRX - P/S Multiple|Forward P/S Multiple Lexicon Pharma
Fundamental company analysis:lexpharma.com LXRX
Core merchandise of Lexicon Pharmaceuticals

The P/S ratio measures the market value of a business relative to its annual sales volume, allowing an investor to assess the premium paid per unit of revenue. The current value of 21.10 for the price-to-sales ratio of Lexicon Pharmaceuticals (LXRX) reflects market expectations for the commercialization of Inpefa, where the expansion of insurance coverage in the US is expected to transform current revenues into a sustainable positive cash flow.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Price-to-Revenue Ratio 89bio, Inc. ETNB|agios.com - Price-to-Revenue Ratio|Structure Therapeutics Inc. - P/S Multiple|Price to Sales MiMedx Group Inc|RZLT (Rezolute Corp) - Market Cap to Revenue|Market Cap to Revenue Ratio MBX|ALT (Altimmune, Inc.) - P/S Multiple|aardvarktherapeutics.com (AARD) - Price-to-Revenue Coefficient|P/S Multiple SGMT|Market Cap to Revenue BioAge Labs BIOA|Price-to-Revenue Ratio Biomea BMEA|Quince Therapeutics Inc (QNCX) - Price to Sales|GUTS - Price-to-Revenue Ratio|VTVT (vTv Therapeutics Inc.) - Market Cap to Revenue Ratio|ATPC (agapeatpgroup.com) - Market Cap to Revenue|Pluri - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synlogic Inc.|Lipocine Corporation - Price-to-Sales Ratio|P/S Multiple MTNB|SPRB (sprucebiosciences.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple GLTO (Galecto)|P/S Multiple Carmell Corp. CTCX|LUMO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ONVO (Organovo Corp)|Radius Recycling, Inc. (RDUS) - Price-to-Revenue Ratio